# Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease

Study · id `cardio:ct-nct03796975` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03796975](<https://clinicaltrials.gov/study/NCT03796975>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03796975

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

## Technical summary

Registry record NCT03796975. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-28 (actual); primary completion 2019-04-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT03796975, source copy `cardio:ctgov-nct03796975-2020-08-07`, retrieved 2026-10-26)
- Started: 2018-06-28 (actual) (ClinicalTrials.gov record NCT03796975, source copy `cardio:ctgov-nct03796975-2020-08-07`, retrieved 2026-10-26)
- Primary completion: 2019-04-28 (actual) (ClinicalTrials.gov record NCT03796975, source copy `cardio:ctgov-nct03796975-2020-08-07`, retrieved 2026-10-26)
- Completion: 2019-11-20 (actual) (ClinicalTrials.gov record NCT03796975, source copy `cardio:ctgov-nct03796975-2020-08-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03796975, source copy `cardio:ctgov-nct03796975-2020-08-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03796975-2020-08-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease
- Condition: Type 2 Diabetes Mellitus
- Condition: Non-alcoholic Fatty Liver Disease
- Condition: Efficacy
- Intervention (Drug): Combination of Pioglitazone and Metformin Tablets
- Intervention (Drug): Metformin Hydrochloride Tablets
- Lead sponsor: Xijing Hospital
- Lead sponsor class: OTHER
- Collaborator: Second Affiliated Hospital of Xi'an Jiaotong University
- Collaborator class: OTHER
- Collaborator: Shaanxi Aerospace Hospital
- Collaborator class: UNKNOWN
- Collaborator: Genertec Universal Xi'an Aero-Engine hospital (Xi' an) Co., Ltd
- Collaborator class: UNKNOWN
- Collaborator: Xi'an Gaoxin Hospital
- Collaborator class: OTHER
- Collaborator: Chang'An Hospital
- Collaborator class: OTHER
- Collaborator: Yan'an People's Hospital
- Collaborator class: OTHER
- Collaborator: Shangluo Central Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Xijing Hospital (`cardio:org-xijing-hospital`)
- Registry lists this organization as a collaborator: Second Affiliated Hospital of Xi'an Jiaotong University (`cardio:org-second-affiliated-hospital-of-xi-an-jiaotong-university`)
- Registry lists this organization as a collaborator: Xi'an Gaoxin Hospital (`cardio:org-xi-an-gaoxin-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study (`cardio:pubmed-37305429`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 47d2994d4cefc4251b2fc7bb32ce911cfdeb4e12357a0f0b539db2efb388bf44
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
